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Background: Results of second-line chemotherapy in patients with extragonadal non-seminomatous
germ cell tumor (NSGCT) appear inferior to results in testicular NSGCT. Patients with retroperi-
toneal NSGCT achieve a comparable long-term survival rate of 30%, but the salvage rates of
patients with mediastinal primary are less than 10%. We conducted a retrospective analysis on
patients with mediastinal and retroperitoneal NSGCT treated with second-line high-dose chemother-
apy (HDCT) registered with the European Group for Blood and Marrow Transplantation (EBMT).
Patients and methods: Between 1987 and 1999, 59 registered patients with retroperitoneal (n = 37)
and mediastinal (n = 22) primary NSGCT, median age 28 years (range 18–60), were treated with
second-line HDCT. All had received cisplatin-containing chemotherapy as first-line treatment.
Results: Toxic death occurred in three cases (5%). With a median follow-up of 58 months (range
14–114), 18/59 patients (30%) continue to be disease-free. Of three patients who had a disease
recurrence after HDCT, one patient achieved a disease-free status with further chemotherapy and
surgery. In total, 19 patients (32%) are currently disease-free. Sixteen of 37 patients (43%) with
retroperitoneal NSGCT, and three of 22 patients (14%) with mediastinal NSGCT are currently alive
and disease-free.
Conclusions: Second-line HDCT might represent a possible option for patients with retroperitoneal
primary NSGCT. New salvage strategies are needed for patients with mediastinal NSGCT.
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Introduction
Germ cell malignancies arising from mediastinum and retro-
peritoneum represent nearly 2% to 5% of all germ cell malig-
nancies in adults [1]. Other extremely rare extragonadal
primary sites are the central nervous system (pineal and/or
pituitary region), liver and lung [2]. Extragonadal and testicu-
lar germ cell tumors differ in some biological, histological
and clinical features. In particular, mediastinal non-seminoma-
tous germ cell tumor (NSGCT) is associated with Klinefelter’s
syndrome and with hematological malignancies, sarcomatous
elements are found more frequently in its pathological speci-
mens, and a poor prognosis is recognized in these patients
[3–6]. Patients with extragonadal NSGCT are included in the
same international staging classification and are treated with
the same chemotherapeutic regimens as patients with testicular
NSGCT [6]. Recently, for the first time, a retrospective study
has focused on second-line chemotherapy in patients with
primary mediastinal and retroperitoneal NSGCT [7]. These
patients appeared to have a survival rate inferior to patients
with testicular NSGCT. Mediastinal primary site and absolute
refractory disease to first-line cisplatin-based chemotherapy
have been identified as independent negative prognostic
factors.
Fossa et al. [8] defined prognostic factors in patients with
NSGCT progressing or relapsing after primary platinum-based
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chemotherapy, identifying a poor prognosis group with no
patient surviving after 3 years. This group included patients
with all the following three prognostic factors: progression-free
interval after first-line chemotherapy of less than 2 years; no
complete remission to induction therapy; and high markers at
relapse [a-fetoprotein >100 ng/ml or b-human chorionic gon-
adotropin (HCG) >100 IU/l]. These results have not been vali-
dated either in extragonadal NSGCT patients or in patients
receiving high-dose chemotherapy (HDCT) as salvage therapy.
Beyer et al. [9] validated a prognostic index for patients
with germ cell tumor receiving HDCT as salvage treatment.
One point each was given for progressive disease before
HDCT and mediastinal primary NSGCT or refractory disease.
Two points were given for b-HCG levels >1000 IU/l before
HDCT or absolute refractory disease. Patients with a cumula-
tive score >_3 were placed in the poor risk category.
To characterize better the role of HDCT in patients with
extragonadal NSGCT, the large database of the patients regis-
tered with the European Group for Blood and Marrow Trans-
plantation (EBMT) was reviewed. This report describes the
EBMT experience of second-line HDCT in patients with
mediastinal and retroperitoneal primary NSGCT.
Patients and methods
Data collection
From December 1987 to December 1999, a total of 160 patients with a
diagnosis of extragonadal germ cell tumor were registered with the
EBMT. The diagnosis of extragonadal germ cell tumor was defined as a
germ cell neoplasm arising in the retroperitoneum, mediastinum or other
location, without demonstrable gonadal (testicular/ovarian) abnormalities
as assessed by ultrasonography. Gonadal biopsies were performed in
patients with abnormalities on gonadal ultrasonography. NSGCTs were
classified as embryonal carcinoma, choriocarcinoma mature or immature
teratoma, yolk sac tumor and mixed germ cell tumors, according to the
World Health Organization classification. Patients with histologically
undifferentiated tumors with markedly elevated serum markers, who were
treated according to germ cell tumor protocols, are included in this report.
We reviewed the registration details of these patients. The reporting phys-
icians were contacted and asked to provide further information on primary
tumor site and extent of disease, histology, tumor markers, initial treat-
ment, second-line chemotherapy, HDCT drugs and toxicities, follow-up
and data on possible secondary neoplasms. For data collection, a standar-
dized questionnaire was sent to each center. All patient data were obtained
in an anonymous manner. Of 160 registered cases, 120 questionnaires
were returned (redemption rate, 75%). Of all these patients, 23 were trea-
ted with HDCT as late-intensification of first-line therapy, nine were trea-
ted with third-, forth- or fifth-line HDCT, four were unknown primary
site, two were pure seminoma and 23 children had been removed from the
present analysis. Overall, we analyzed 59 cases of primary mediastinal
and retroperitoneal NSGCTs treated with second-line HDCT from 29 cen-
ters in Europe. As this is a report of registry data, there are cases where
information is incomplete, as indicated in the tables.
Patient characteristics
Details of the 59 patients with extragonadal NSGCT relapsing after or
during primary cisplatin-based chemotherapy are listed in Table 1. The
median age was 28 years (range 18–60). Fifty-five patients were male and
four were female. Thirty-seven patients (63%) had primary retroperitoneal
and 22 (37%) had primary mediastinal NSGCT. The majority (n = 37,
63%) of these patients received cisplatin, etoposide and bleomycin (PEB)
as first-line chemotherapy. Table 2 summarizes first-line chemotherapy
regimens and response.
Salvage treatment
All patients received salvage HDCT as second-line treatment. The salvage
HDCT regimens for extragonadal NSGCT patients were adapted based on
the chemotherapeutic regimens given as initial therapy and the salvage
HDCT protocols used in each center for NSGCT, including carboplatin,
etoposide and other drugs proven to be active in NSGCT. Before HDCT,
45 (74%) patients received an induction and/or mobilizing regimen, more
frequently VIP (cisplatin, etoposide and ifosfamide) (n = 24, 41%), while
14 (24%) patients were treated with up-front HDCT. Table 3 summarizes
induction and/or mobilizing regimens and response. Thirty-eight patients
received one course of HDCT, 18 patients received two courses, two
patients received three courses, and in one case four courses were given.
The most commonly used HDCT protocols were based on high-doses of
carboplatin and etoposide, with or without another high-dose chemothera-
peutic agent (Table 4). Hematopoietic support consisted of peripheral
blood progenitor cells in 44 courses, and autologous bone marrow trans-
plantation in 28.
Table 1. Characteristics of patients receiving second-line HDCT
according to primary tumor site
Mediastinum Retroperitoneum Total
No. of patients 22 37 59
Male/female 21/1 34/3 55/4
Age (years)
Median 28.5 28 28
Range 18–55 19–60 18–60
Histology
Embryonal carcinoma 7 8 15
Choriocarcinoma 1 6 7
Immature teratoma 3 3 6
Yolk sac tumor 1 3 4
Mixed 9 13 22
Unknown 0 5 5
Sites of disease
Lung 6 16 22
Retroperitoneum 0 20 20
Mediastinum 15 4 19
Liver 4 10 14
Bone 4 0 4
Brain 1 2 3
Others 4 2 6
Unknown 3 11 14
Elevated serum tumor marker
a-fetoprotein >100 ng/ml 5 5 3 8
b-HCG >100 IU/l 1 6 7
HDCT, high-dose chemotherapy; b-HCG, b-human chorionic
gonadotropin.
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Definitions
Tumor response was classified as follows. Complete remission (CR) was
defined as a complete disappearance of all clinical, radiological and bio-
chemical evidence of disease, with normalization of the tumor markers,
b-HCG and/or a-fetoprotein and/or lactate dehydrogenase, for at least a
1-month duration. A partial response was defined as a decrease in 50% or
more of the sum of the products of perpendicular diameters of measurable
disease, lasting for at least 1 month. If elevated markers were the only
evidence of disease, a decrease of 90% or greater was required for a partial
response (PR). In addition, reduction of the size of a tumor lesion and
normalization of previously elevated tumor markers was considered a par-
tial remission with tumor marker normalization (PR–), whereas a reduction
>_ 50% in the sum of the perpendicular diameters of measurable disease plus
a tumor marker decrease for at least 1 month, but without complete normal-
ization, was considered a marker positive partial remission (PR+). Stable
disease (SD) was defined as a decrease <50% or an increase <25% in bidi-
mensional tumor measurements or stable tumor marker levels. Progressive
disease (PD) was defined as either residual lesions increasing in size or as
occurrence of new lesions and/or elevation of tumor markers at repeated
controls. Patients who achieved a normalization of tumor markers but an
incomplete radiographic response were submitted to postchemotherapy sur-
gery. However, in some patients who had attained serological CR, but with
persistent minor radiographic abnormalities, individual investigators had
chosen to observe such patients without surgery. Those patients were for-
mally coded as PRs if their residual abnormalities remained stable or
decreased on imaging studies over a 1-year period. Toxicity was evaluated
according to World Health Organization classification [10].
Statistical analysis
Descriptive statistics are presented as the median and range. Duration of
follow-up and survival in this analysis were calculated based on the date
of the first day of salvage chemotherapy until the date of last contact, if
the patient was still alive, or until the date of death. Probabilities of dis-
ease-free and overall survival were calculated using the Kaplan–Meier
product limit estimate [11]. The log-rank test was used for comparisons of
overall survival between groups [12]. A P value of <0.05 was considered
to be significant.
Results
Toxicity
Toxicity data were fully assessable for 68 (81%) of 84 HDCT
cycles delivered. Treatment-related death occurred in three
Table 3. Second-line induction/mobilizing regimens and response
according to primary tumor site
Mediastinum
(n = 22)
[n (%)]
Retroperitoneum
(n = 37)
[n (%)]
Total
(n = 59)
[n (%)]
Induction/mobilizing regimen
Cisplatin/etoposide/
ifosfamide
11 (50) 13 (35) 24 (41)
Cisplatin/ifosfamide/
vinblastine
2 (9) 3 (8) 5 (8)
Other platinum-containing
regimen
2 (9) 7 (19) 9 (15)
Other non platinum-containing
regimen
2 (9) 5 (14) 7 (12)
No induction/mobilizing
regimen
5 (23) 9 (24) 14 (24)
Response
Complete remission 2 (9) 3 (8) 5 (8)
Partial remission, negative
marker
4 (18) 11 (30) 15 (25)
Partial remission, positive
marker
4 (18) 10 (27) 14 (24)
Stable disease 4 (18) 1 (3) 5 (8)
Progressive disease 1 (5) 2 (5) 3 (5)
Unknown/not assessed 2 (9) 1 (3) 3 (5)
No induction/mobilizing
regimen
5 (23) 9 (24) 14 (24)
Table 4. Second-line HDCT regimens according to primary tumor site
Mediastinum
[n (%)]
Retroperitoneum
[n (%)]
Total
[n (%)]
No. of HDCT courses 31 53 84
Carboplatin–etoposide-based
HDCT regimen
Carboplatin/etoposide/
cyclophosphamide
8 (26) 15 (28) 23 (26)
Carboplatin/etoposide/
ifosfamide
7 (23) 11 (21) 18 (20)
Carboplatin/etoposide/
thiotepa
1 (3) 4 (8) 5 (6)
Carboplatin/etoposide/
paclitaxel
2 (6) 2 (4) 4 (5)
Carboplatin/etoposide 5 (16) 9 (17) 14 (17)
Other platinum-based HDCT regimen
Cisplatin/etoposide/
cyclophosphamide or
ifosfamide
6 (19) 4 (8) 10 (12)
Other platinum-based regimen 2 (6) 5 (9) 7 (8)
Cyclophosphamide/thiotepa
HDCT regimen
0 3 (6) 3 (4)
HDCT, high-dose chemotherapy.
Table 2. Primary chemotherapy regimens and response according to
primary tumor site
Mediastinum
(n = 22)
[n (%)]
Retroperitoneum
(n = 37)
[n (%)]
Total
(n = 59)
[n (%)]
First-line chemotherapy
Cisplatin/etoposide/bleomycin 14 (64) 23 (62) 37 (63)
Cisplatin/etoposide/ifosfamide 4 (18) 5 (14) 9 (15)
Other platinum-containing
regimen
4 (18) 9 (24) 13 (22)
Response
Complete remission 10 (45) 9 (24) 19 (32)
Partial remission, negative
marker
1 (5) 13 (35) 14 (24)
Partial remission, positive
marker
8 (36) 13 (35) 21 (36)
Stable disease 2 (9) 1 (3) 3 (5)
Progressive disease 0 1 (3) 1 (2)
Unknown 1 (5) 0 1 (2)
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patients with mediastinal NSGCT after HDCT. The cause was
acute respiratory distress syndrome (n = 1), pneumonia (n = 1)
and mediastinal hemorrhage (n = 1). The median time to
recovery to an absolute neutrophil count >500/ml and a plate-
let count >20 000/ml, was 9.5 days (range 0–32) and 10 days
(range 0–34), respectively. The median number of transfu-
sions of red blood cell and platelet bags was five (range 0–
27) and six (range 0–35), respectively. Fever occurred in 53
(78%) patients with an overall median duration of 3 days
(range 0–20). The number of HDCT courses with episodes of
clinically documented infections was 28 (42%). The following
non-hematological side-effects were the most relevant: grade
>_3 stomatitis was reported in 28 courses, grade >_3 peripheral
neurotoxicity in eight, grade >_3 renal toxicity in three, grade
>_3 ototoxicity in two, veno-occlusive disease in one case, gas-
trointestinal hemorrhage in one and pulmonary hemorrhage in
one. No patients developed myelodysplasia or secondary
neoplasms after HDCT.
Response and survival
Overall, 21 (36%) patients achieved a CR. Of these patients,
16 obtained a radiological CR, the other five achieved a radio-
logical PR– and received post-HDCT resection of residual
masses without evidence of viable malignant cells. Sixteen of
37 patients (43%) with retroperitoneal primary NSGCT, and
five of 22 patients (23%) with mediastinal primary NSGCT
achieved a CR. Results are presented in detail in Table 5. The
median follow-up period for all patients was 14 months (range
1–114) and 58 months (range 14–114) for surviving patients.
Eighteen of 59 patients (30%) continue to be disease-free. Of
three patients who had a disease recurrence after HDCT, one
underwent further chemotherapy and surgery and achieved a
disease-free status. In total, 19 patients (32%) are currently
disease-free (Table 5). Sixteen of 37 patients (43%) with retro-
peritoneal primary NSGCT, and three of 22 patients (14%)
with mediastinal primary NSGCT are currently alive and
disease-free. Figure 1 illustrates the outcome of patients with
extragonadal NSGCT, according to the primary site. The
median survival time was 28 months for patients with
retroperitoneal NSGCT, and 11 months for patients with med-
iastinal primary. The 3-year overall survival rates were 48%
and 14%, respectively.
According to the predictive score derived from the study of
Fossa et al. [8], 13 patients with all three risk factors were
identified with a median overall survival of 11 months (range
3–16). None of these patients achieved a disease-free status.
According to the prognostic index validated by Beyer et al.
[9], the only two patients stratified into the poor risk category
died of disease after 5 and 14 months, respectively.
Discussion
In this report, we have presented the results of the EBMT
experience with HDCT as second-line treatment for patients
with extragonadal NSGCT. To the best of our knowledge, this
is the largest experience with HDCT in this setting. With a
median follow-up of 58 months (range 14–114), of 59 extra-
gonadal NSGCT patients who received second-line HDCT, 18
(30%) have been disease-free continuously. Since another
patient with disease recurrence achieved a disease-free status
after further chemotherapy, 19 extragonadal NSGCT patients
(32%) are currently disease-free: 16/37 patients (43%) with
retroperitoneal primary NSGCT, and three of 22 patients
(14%) with mediastinal primary.
We analyzed our results according to the prognostic index
validated by the study of Fossa et al., which identified a poor
Table 5. Second-line HDCT: response and outcome according to primary
tumor site
Mediastinum
(n = 22)
[n (%)]
Retroperitoneum
(n = 37)
[n (%)]
Total
(n = 59)
[n (%)]
Response
Complete remissiona 5 (23) 16 (43) 21 (36)
Partial remission with
negative marker 1
(5) 7 (19) 8 (14)
Partial remission with
positive marker 3
(14) 6 (16) 9 (15)
Stable disease 4 (18) 2 (5) 6 (10)
Progressive disease 6 (27) 4 (11) 10 (17)
Treatment-related
death
3 (14) 0 3 (5)
Unknown 0 2 (5) 2 (3)
Outcome
Alive continuously
disease-free
3 (14) 15 (41) 18 (30)
Alive currently disease-freeb 0 1 (3) 1 (2)
Alive with disease 0 1 (3) 1 (2)
Dead of disease 16 (73) 20 (54) 36 (61)
Treatment-related death 3 (14) 0 3 (5)
aFive patients obtaining a partial remission with negative marker and
receiving post-HDCT resection of residual masses without evidence of
viable malignant cells were also included in this group.
bPatient with disease recurrence achieving a second disease-free status
after further chemotherapy and surgery.
HDCT, high-dose chemotherapy.
Figure 1. Overall survival for patients with mediastinal and retroperito-
neal germ cell tumor (GCT).
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prognosis group of NSGCT patients progressing after plati-
num-based first-line chemotherapy [8]. Patients with all three
risk factors had a very poor prognosis and none of these
patients survived beyond 16 months. Therefore, in the EBMT
experience, the prognostic index also predicted outcome in
patients with extragonadal NSGCT who received HDCT as
salvage treatment.
In addition, we evaluated our results according to the Beyer
prognostic classification for patients with germ cell tumor,
treated with salvage HDCT [9]. Only two patients were strati-
fied into the poor risk category and died of disease after 5 and
14 months, respectively. The publication in 1996 of the Beyer
classification could have induced a better patient selection for
salvage HDCT.
Several studies of salvage chemotherapy for patients with
NSGCT included patients with extragonadal primary, but
these patients usually represented a small percentage. Loehrer
et al. [13] reported the largest experience with vinblastine,
ifosfamide and cisplatin as second-line therapy for germ cell
tumor. None of the 32 patients with non-seminomatous extra-
gonadal tumors are disease-free compared with 30 of 100
patients with gonadal primaries. Other studies have investi-
gated the use of HDCT in patients with relapsed NSGCT [9,
14–16]. Saxman et al. [14] presented a series of 73 extragona-
dal NSGCT treated with salvage chemotherapy. Only 7% of
their patients achieved long-term disease-free survival. None
of the 28 patients who received HDCT as initial salvage treat-
ment (n = 8) and as third-line treatment (n = 20) were long-
term disease-free. In the large multivariate analysis reported
by Beyer et al., including 282 patients with germ cell tumors
treated with salvage HDCT, mediastinal primary site and
refractory disease were identified as the most important poor
prognostic factors [9]. Recently, Vaena et al. [15] showed a
37% long-term survival rate in 63 patients with platinum-
refractory germ cell tumors treated with early tandem HDCT,
but no patients with mediastinal primary NSGCT survived dis-
ease-free at 2 years.
In the largest reported series including 142 patients with
relapsed extragonadal NSGCT treated with second-line
chemotherapy, patients with retroperitoneal primary NSGCT
achieved a long-term survival rate of 30%, but those with
mediastinal primary had salvage rates of less than 10% [7].
Both primary mediastinal location and refractoriness to cispla-
tin were found to be independent negative factors. In this
series, 28% of patients with mediastinal primary and 41% of
patients with retroperitoneal NSGCT were treated with
second-line HDCT. The median survival time was 15 months
for patients receiving HDCT and 11 months for patients trea-
ted with standard-dose chemotherapy. Although, the survival
curves are in favor of HDCT, there was no statistically signifi-
cant difference between both groups in term of median sur-
vival (P = 0.27). However, seven of 22 (32%) patients with
retroperitoneal NSGCT receiving HDCT and 11/39 (28%)
who underwent conventional-dose chemotherapy were alive
without disease. In total, the 3-year overall survival for the
subpopulation of patients with chemosensitive retroperitoneal
primary NSGCT was 26%, while for patients with chemo-
sensitive mediastinal primary it was 11%.
In the EBMT experience, all extragonadal NSGCT patients,
but one, were chemosensitive (Table 2). The 3-year overall
survival for patients with retroperitoneal primary NSGCT was
48%, while for patients with mediastinal primary it was 14%,
as shown in Figure 1. Results in the subset of chemosensitive
retroperitoneal NSGCT might appear in favor of the use of
second-line HDCT, while HDCT has no substantial impact on
the outcome of patients with mediastinal primary site. How-
ever, this hypothesis must be considered with caution because
a systematic bias based on patient selection for HDCT might
have influenced these findings.
In order to clarify the exact role of HDCT in patients with
chemosensitive germ cell tumors, a phase III randomized
study performed by EBMT (IT-94 study) was carried out [17].
This trial compared four courses of conventional salvage che-
motherapy with three courses of the same regimen followed
by one single shot of HDCT. Definitive results will possibly
better define the role of HDCT in the subpopulation of
patients with extragonadal NSGCT, but the number of these
patients, not included in the present analysis, was too limited
to draw any firm conclusion.
In summary, results of the EBMT experience showed a
possible role for second-line HDCT for chemosensitive
patients with retroperitoneal NSGCT. Final results from larger
studies could eventually better define the role of salvage
HDCT for patients with extragonadal NSGCT. New strategies
are needed for salvage treatment of patients with mediastinal
NSGCT.
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Baumgartner, Wilhelminenspital, Vienna, Austria; B. Lioure,
University Hospital, Strasbourg, France; A. Gratwohl, Kan-
tonsspital Basel, Switzerland; B. Hertenstein, K. Welte,
R. Blasczyk, University Hospital, Hannover, Germany;
Y. Beguin, University Hospital, Liege, Belgium; B. Metzner,
University Hospital, Oldenburg, Germany; K. Orchard, Gen-
eral Hospital, Southampton, UK; J. Garcia-Conde, University
Hospital, Valencia, Spain; C. Devalck, Saint-Pierre University
Hospital, Brussels, Belgium; A. D. Moicean, Victor Babes
Institute, Bucharest, Romania; R. Marcus, Addenbrooke’s
Hospital, Cambridge, UK; S. McCann, St James’s Hospital
and University, Dublin, Ireland; S. A. Schey, King’s College
London Medical School, London, UK; G. Juliusson, Univer-
sity Hospital, Linko¨ping, Sweden; S. Lenhoff, University Hos-
pital, Lund, Sweden; K. Kolbe, Johannes Gutenberg
University, Mainz, Germany; E. Morra, Niguarda Ca’ Granda
Hospital, Milan, Italy; J. F. Rossi, University Hospital, Mon-
tpellier, France; I. Yaniv, Schneider Children’s Medical Cen-
ter, Petah Tikva, Israel; V. Koza, Charles University Hospital,
Pilsen, Czech Republic; M. Freund, University Hospital,
Rostock, Germany; M. Bjorkholm, Karolinska Hospital and
Institute, Stockholm, Sweden; H. Greinix, University Hospital,
Vienna, Austria; W. Hinterberger, Donauspital, Vienna,
Austria; T. Demirer, A. Kulekci, Ankara University Medical
School, Ankara, Turkey.
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